A3334|cas:854171-31-6|西域试剂

A3334,99.86%

产品编号：Bellancom-131448| CAS NO：854171-31-6| 分子式：C₁₇H₁₃N₃O₃| 分子量：307.30

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-131448	￥3500.00	杭州北京（现货）
Bellancom-131448	￥5800.00	杭州北京（现货）
Bellancom-131448	￥16500.00	杭州北京（现货）
Bellancom-131448	￥25500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

A3334

产品介绍

A3051 是一种有效的和具有口服活性的 CXXC5-DVL 的抑制剂，IC₅₀ 值为 63.06 nM。A3334 可用于研究高脂肪饮食 (HFD) 和蛋氨酸-胆碱缺乏饮食 (MCD) 诱导的疾病，例如肥胖，糖尿病和NASH。详细信息请参考专利文献 WO2020079569。

生物活性

A3051 is a potent and orally active inhibtor of CXXC5-DVL extracted from patent WO2020079569, has an IC₅₀ of 63.06 nM. A3334 can be used for the research of high fat diet (HFD)-induced and methionine-choline deficient diet (MCD)-induced phenotypes such as obesity, diabetes, and NASH.

体外研究

A3334 (1-10 μM) efficiently inhibits the adipogenic differentiation of 3T3-L1 preadipocytes via the Wnt/β-eatenin signaling pathway.
A3334 (1-10 μM; 24 h) enhances the TOPFlash reporter activity in HEK293-TOP cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

A3334 (25 mg/kg; p.o. once daily for 16 weeks) has anti-obesity effects in the HFD mice, and has no effect on mice fed with normal diet.
A3334 (25 mg/kg; p.o. once daily for 5 days) significantly reduces fasting glucose and the levels of glucose tolerance (GTT) and insulin tolerance (ITT) in serum in mice.
A3334 (25 mg/kg; p.o. once daily for 3 weeks) significantly abolishes hepatosteatosis and the increased levels of alanine transaminase (ALT) and aspartatetransaminase (AST) in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6N mice (6-week-old) are fed on the high fat die (HFD) for 16 weeks
Dosage:	25 mg/kg
Administration:	P.o. daily for 16 weeks
Result:	Not observed the HFD-induced body weight gain and abdominal obesity. Reduced the level of triglyceride and total cholesterol and increased the level of HDL-cholesterol. Suppressed the increase in adipocyte cell sizes and enhancement of inflammation.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6N mice (6-week-old) are fed on the high fat die (HFD) for 16 weeks
Dosage:	25 mg/kg
Administration:	P.o. daily for 16 weeks
Result:	Not observed the HFD-induced body weight gain and abdominal obesity. Reduced the level of triglyceride and total cholesterol and increased the level of HDL-cholesterol. Suppressed the increase in adipocyte cell sizes and enhancement of inflammation.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (813.54 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2541 mL	16.2707 mL	32.5415 mL
5 mM	0.6508 mL	3.2541 mL	6.5083 mL
10 mM	0.3254 mL	1.6271 mL	3.2541 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.77 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.77 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液